Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
doi: 10.1007/s00125-009-1643-x 87 XuQZhangXLiTShaoS
It is a common form of heart failure in patients with obesity, hypertension, and metabolic syndrome, and it has become a recognized clinical target for incretin-based therapy following the STEP-HFpEF trial (semaglutide in HFpEF with obesity) and the SUMMIT trial (tirzepatide in obesity-related HFpEF)
How long will it be until you see the full results
Human gut microbiota changes reveal the progression of glucose intolerance
US$ 29.34
US$ 23.40
US$ 28.94
US$ 25.93
US$ 25.60
